(+) -JNJ-A07

• Description:

  (+) -JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. (+) -JNJ-A07 exerts nanomolar to picomolar activity against a panel of 21 clinical isolates. (+) -JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models[1].

• UNSPSC:

  12352005

• Target:

  Dengue Virus; Flavivirus; Virus Protease

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/plus-jnj-a07.html

• Concentration:

  10mM

• Purity:

  98.46

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  OC(CCCOC1=CC(OC)=CC(NC(C2=CC=C(C=C2)Cl)C(N3C4=CC(OC(F)(F)F)=CC=C4CC3)=O)=C1)=O.[Rotation(+)]

• Molecular Formula:

  C28H26ClF3N2O6

• Molecular Weight:

  578.96

• References & Citations:

  [1]Kaptein SJF, et al. A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction [published correction appears in Nature. 2021 Nov;599 (7883) :E2]. Nature. 2021;598 (7881) :504-509.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2135640-93-4]